Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil
Abstract Background Triple-negative breast cancer (TNBC) is a heterogeneous disease that represents 10–20% of breast cancer cases. The prognosis for advanced TNBC is usually poor, with a median overall survival of approximately 18 months or less. Main text New targeted therapies such as anti-PD-L1 a...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-04-01
|
| Series: | Surgical and Experimental Pathology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s42047-021-00092-5 |
| _version_ | 1819291240604106752 |
|---|---|
| author | Kátia Ramos Moreira Leite Carlos Henrique Barrios Antônio Carlos Buzaid Débora Gagliato Helenice Gobbi Fernando Soares |
| author_facet | Kátia Ramos Moreira Leite Carlos Henrique Barrios Antônio Carlos Buzaid Débora Gagliato Helenice Gobbi Fernando Soares |
| author_sort | Kátia Ramos Moreira Leite |
| collection | DOAJ |
| description | Abstract Background Triple-negative breast cancer (TNBC) is a heterogeneous disease that represents 10–20% of breast cancer cases. The prognosis for advanced TNBC is usually poor, with a median overall survival of approximately 18 months or less. Main text New targeted therapies such as anti-PD-L1 agents are emerging as an option to treat advanced TNBC. A panel of 6 national experts with an active interest in breast cancer convened online. Panel members had either clinical or pathology experience in breast cancer. The experts pre-defined critical questions in the management of PD-L1 in TNBC, and a literature review was performed for selected topics before the online meeting. Conclusion The experts led active discussions involving a multidisciplinary team comprising pathologists and clinical oncologists. The meeting served to discuss the most relevant issues. A total of 10 critical questions for PD-L1+ TNBC were debated and are presented in this review. This article discusses the current landscape for PD-L1 tests in TNBC in Brazil. |
| first_indexed | 2024-12-24T03:35:30Z |
| format | Article |
| id | doaj.art-45d022ef4af0442cb9f36a1e2c47d33b |
| institution | Directory Open Access Journal |
| issn | 2520-8454 |
| language | English |
| last_indexed | 2024-12-24T03:35:30Z |
| publishDate | 2021-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Surgical and Experimental Pathology |
| spelling | doaj.art-45d022ef4af0442cb9f36a1e2c47d33b2022-12-21T17:17:05ZengBMCSurgical and Experimental Pathology2520-84542021-04-01411810.1186/s42047-021-00092-5Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in BrazilKátia Ramos Moreira Leite0Carlos Henrique Barrios1Antônio Carlos Buzaid2Débora Gagliato3Helenice Gobbi4Fernando Soares5Faculdade de Medicina da Universidade de São PauloLatin American Cooperative Oncology Group – LACOGHospital Beneficência PortuguesaHospital Beneficência PortuguesaDisciplina de Patologia Especial, Universidade Federal do Triângulo MineiroInstituto de Anatomia Patológica, Rede D’Or São LuizAbstract Background Triple-negative breast cancer (TNBC) is a heterogeneous disease that represents 10–20% of breast cancer cases. The prognosis for advanced TNBC is usually poor, with a median overall survival of approximately 18 months or less. Main text New targeted therapies such as anti-PD-L1 agents are emerging as an option to treat advanced TNBC. A panel of 6 national experts with an active interest in breast cancer convened online. Panel members had either clinical or pathology experience in breast cancer. The experts pre-defined critical questions in the management of PD-L1 in TNBC, and a literature review was performed for selected topics before the online meeting. Conclusion The experts led active discussions involving a multidisciplinary team comprising pathologists and clinical oncologists. The meeting served to discuss the most relevant issues. A total of 10 critical questions for PD-L1+ TNBC were debated and are presented in this review. This article discusses the current landscape for PD-L1 tests in TNBC in Brazil.https://doi.org/10.1186/s42047-021-00092-5Triple-negative breast cancerTarget therapyImmunohistochemistryPD-L1Immune checkpoint inhibitor |
| spellingShingle | Kátia Ramos Moreira Leite Carlos Henrique Barrios Antônio Carlos Buzaid Débora Gagliato Helenice Gobbi Fernando Soares Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil Surgical and Experimental Pathology Triple-negative breast cancer Target therapy Immunohistochemistry PD-L1 Immune checkpoint inhibitor |
| title | Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil |
| title_full | Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil |
| title_fullStr | Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil |
| title_full_unstemmed | Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil |
| title_short | Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil |
| title_sort | applicability of pd l1 tests to tailor triple negative breast cancer treatment in brazil |
| topic | Triple-negative breast cancer Target therapy Immunohistochemistry PD-L1 Immune checkpoint inhibitor |
| url | https://doi.org/10.1186/s42047-021-00092-5 |
| work_keys_str_mv | AT katiaramosmoreiraleite applicabilityofpdl1teststotailortriplenegativebreastcancertreatmentinbrazil AT carloshenriquebarrios applicabilityofpdl1teststotailortriplenegativebreastcancertreatmentinbrazil AT antoniocarlosbuzaid applicabilityofpdl1teststotailortriplenegativebreastcancertreatmentinbrazil AT deboragagliato applicabilityofpdl1teststotailortriplenegativebreastcancertreatmentinbrazil AT helenicegobbi applicabilityofpdl1teststotailortriplenegativebreastcancertreatmentinbrazil AT fernandosoares applicabilityofpdl1teststotailortriplenegativebreastcancertreatmentinbrazil |